01.07.2024 • News

Kemira Acquires Norit’s UK Reactivation Operations

In a move to enter the activated carbon market for micropollutants removal, Finnish chemicals company Kemira has agreed to purchase Norit’s UK reactivation business from Purton Carbons. The deal is expected to close in the third quarter of2024. Financial details of the deal were not disclosed.

Activated carbon is the most common technology to remove odor and taste in drinking water, as well as micropollutants including per- and polyfluoroalkyl substances (PFAS) in water treatment applications. Micropollutant removal, Kemira said, is expected to become increasingly relevant for water and wastewater treatment plants due to growing concern for consumer health and environmental safety. In addition, PFAS removal from drinking water and micropollutant removal from wastewater have been introduced in recent EU regulation updates.

The scope of the agreement includes the reactivation facility in Purton, UK. Reactivation regenerates spent granular or pelletized activated carbons, making them ready for another reuse cycle. The acquired facility produces the Green reactivation brand for potable water and food-related applications, as well as the Amber reactivation brand which is used for other non-food related applications. Revenue of the acquired plant in 2023 was several millions of euros and nine employees will transfer to Kemira as part of the transaction, the company stated.

Tuija Pohjolainen-Hiltunen, president of Kemira’s Industry & Water business, said: “PFAS and other micropollutants removal from water is increasingly relevant for our customers who are compelled to comply with regulations around consumer and environmental health. Acquiring Norit’s UK carbon reactivation business bolsters our portfolio and strengthens our water treatment offering, allowing us to capitalize on a rising demand in Europe.”

© Shutterstock / kzww
© Shutterstock / kzww

Company

Logo:

Kemira Oyj

Energiakatu 4
00101 Helsinki
Finland

Company contact







Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.